Open Access

ARTICLE

Molecular targeted therapies for renal cell carcinoma

Sam D. Graham, Jr.^1,2, Mary Elizabeth Warden¹, Jeffrey Lou^1,3

1 Urologic Specialists of Virginia, Richmond, Virginia, USA
2 Thomas Johns Cancer Hospital, Richmond, Virginia, USA
3 Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA
Address correspondence to Dr. Sam D. Graham, Urologic Specialists of Virginia, 7135 Jahnke Road, Richmond, Virginia 23225 USA

Canadian Journal of Urology 2007, 14(Suppl.6), 48-52.

Abstract

New advances in technology to directly target specific molecular events in the proliferation of cancer have led to promising results in renal cell carcinoma. Response rates in excess of 70% and complete responses in advanced (metastatic) renal cell carcinoma have caused a change in the paradigm of treatment from immunotherapy. Toxicities are significant, but manageable and pushing the toxicity to tolerability may increase the response rate.

---

Keywords

---